메뉴 건너뛰기
New England Journal of Medicine
Volumn 367, Issue 13, 2012, Pages 1256-1257
Enzalutamide - A major advance in the treatment of metastatic prostate cancer
Author keywords

[No Author keywords available]
Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ARN 509; BICALUTAMIDE; ENZALUTAMIDE; FLUTAMIDE; NILUTAMIDE; PLACEBO; UNCLASSIFIED DRUG;
EID: 84866752804     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1209041     Document Type: Editorial
Times cited : (20)
References (9)
  • 1
    • 84866770294 scopus 로고    scopus 로고
    • Increased survival with enzalutamide in prostate cancer after chemotherapy
    • Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
    • (2012) N Engl J Med , vol.367 , pp. 1187-1197
    • Scher, H.I.1    Fizazi, K.2    Saad, F.3
  • 2
    • 0023180623 scopus 로고
    • A novel non-steroidal, peripherally selective antiandrogen
    • Furr BJ, Valcaccia B, Curry B, Woodburn JR, Chesterson G, Tucker H. ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen. J Endocrinol 1987;113:R7-R9. (Pubitemid 17112907)
    • (1987) Journal of Endocrinology , vol.113 , Issue.3
    • Furr, B.J.A.1    Valcaccia, B.2    Curry, B.3
  • 3
    • 0031017228 scopus 로고    scopus 로고
    • Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm
    • Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997;15:382-8. (Pubitemid 27021526)
    • (1997) Journal of Clinical Oncology , vol.15 , Issue.1 , pp. 382-388
    • Small, E.J.1    Vogelzang, N.J.2
  • 4
    • 68149098902 scopus 로고    scopus 로고
    • Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival
    • Akaza H, Hinotsu S, Usami M, et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009;115:3437-45.
    • (2009) Cancer , vol.115 , pp. 3437-3445
    • Akaza, H.1    Hinotsu, S.2    Usami, M.3
  • 6
    • 77952105685 scopus 로고    scopus 로고
    • Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study
    • Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46.
    • (2010) Lancet , vol.375 , pp. 1437-1446
    • Scher, H.I.1    Beer, T.M.2    Higano, C.S.3
  • 7
    • 79957443342 scopus 로고    scopus 로고
    • Abiraterone and increased survival in metastatic prostate cancer
    • de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
    • (2011) N Engl J Med , vol.364 , pp. 1995-2005
    • De Bono, J.S.1    Logothetis, C.J.2    Molina, A.3
  • 8
    • 84863013857 scopus 로고    scopus 로고
    • Modeling a lethal prostate cancer variant with small-cell carcinoma features
    • Tzelepi V, Zhang J, Lu JF, et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 2012;18:666-77.
    • (2012) Clin Cancer Res , vol.18 , pp. 666-677
    • Tzelepi, V.1    Zhang, J.2    Lu, J.F.3
  • 9
    • 84863230424 scopus 로고    scopus 로고
    • ARN-509: A novel antiandrogen for prostate cancer treatment
    • Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012;72:1494-503.
    • (2012) Cancer Res , vol.72 , pp. 1494-1503
    • Clegg, N.J.1    Wongvipat, J.2    Joseph, J.D.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.